AeroRx Therapeutics

LA JOLLA, CA · Founded 2024 · Biotech · Private

Nebulized combination therapies for COPD

Claim this profile

Follows are private to you and power your alerts

Updated · aerorxtx.com

Sector
Biotech
Headquarters
LA JOLLA, CA
Founded
2024
Latest Form D
$10.4M, Oct 2025
Total capital
$10.4M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$10.4M
1 Form D · last Oct 2025
13 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
2
8 pending · first 2023
Rank in peer group#397 of 1449

Capital timeline

2025FEDERAL ↑EQUITY ↓Cumulative $10.4M1st Form D$10.4M
2025FEDERAL ↑EQUITY ↓Cumulative $10.4M1st Form D$10.4M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$10.4M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#397 · top 27%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Ahmet Tutuncu, M.D., Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
  • Heather Stuart Preston, M.D.DirectorNamed in SEC Form D filings
  • Jay B. Lichter, Ph.D.DirectorNamed in SEC Form D filings
  • John Stuart Patton, Ph.D.DirectorNamed in SEC Form D filings
  • Sanford Madigan, Ph.D.DirectorNamed in SEC Form D filings
  • Tighe ReardonExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 10
  • PendingLiquid Formulations Of IndacaterolUSPTOApplication 19315294
  • GrantedLiquid Formulations Of IndacaterolUSPTOUS 12,419,883
  • PendingLiquid Formulations Of Indacaterol And GlycopyrroniumUSPTOApplication 18852135
Show all 10 patent records
  • Liquid Formulations Of IndacaterolMar 19, 2026 · Application 19315294Pending
  • Liquid Formulations Of IndacaterolSep 23, 2025 · US 12,419,883Granted
  • Liquid Formulations Of Indacaterol And GlycopyrroniumJun 5, 2025 · Application 18852135Pending
  • Liquid Formulations Of IndacaterolDec 19, 2023 · US 11,844,793Granted
  • Liquid Formulations Of Indacaterol And GlycopyrroniumApplication 63325510Pending
  • Liquid Formulations Of IndacaterolApplication PCTUS2021071646Pending
  • Liquid Formulations Of Indacaterol And GlycopyrroniumApplication PCTUS2023016847Pending
  • Liquid Formulations Of Indacaterol And GlycopyrroniumApplication PCTUS2024022018Pending
  • Liquid Formulations Of Indacaterol And GlycopyrroniumApplication 19470557Pending
  • Liquid Formulations Of Indacaterol And GlycopyrroniumApplication 63455909Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .